Scowcroft H (2011년 9월 21일). “Where did abiraterone come from?”. 《Journal of Medicinal Chemistry》 (Cancer Research UK) 38 (13): 2463–2471. 2011년 9월 25일에 원본 문서에서 보존된 문서. 2011년 9월 28일에 확인함.
doi.org
dx.doi.org
Potter GA, Barrie SE, Jarman M, Rowlands MG (June 1995). “Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer”. 《Journal of Medicinal Chemistry》 38 (13): 2463–2471. doi:10.1021/jm00013a022. PMID7608911.지원되지 않는 변수 무시됨: |name-list-style= (도움말)
Luthy IA, Begin DJ, Labrie F (November 1988). “Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture”. 《Journal of Steroid Biochemistry》 31 (5): 845–52. doi:10.1016/0022-4731(88)90295-6. PMID2462135.
Dhondt B, Buelens S, Van Besien J, Beysens M, De Bleser E, Ost P, Lumen N (2019). “Abiraterone and spironolactone in prostate cancer: a combination to avoid”. 《Acta Clinica Belgica》 74 (6): 439–444. doi:10.1080/17843286.2018.1543827. PMID30477405. S2CID53738534.
World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). 《World Health Organization model list of essential medicines: 22nd list (2021)》. Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Potter GA, Barrie SE, Jarman M, Rowlands MG (June 1995). “Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer”. 《Journal of Medicinal Chemistry》 38 (13): 2463–2471. doi:10.1021/jm00013a022. PMID7608911.지원되지 않는 변수 무시됨: |name-list-style= (도움말)
Luthy IA, Begin DJ, Labrie F (November 1988). “Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture”. 《Journal of Steroid Biochemistry》 31 (5): 845–52. doi:10.1016/0022-4731(88)90295-6. PMID2462135.
Dhondt B, Buelens S, Van Besien J, Beysens M, De Bleser E, Ost P, Lumen N (2019). “Abiraterone and spironolactone in prostate cancer: a combination to avoid”. 《Acta Clinica Belgica》 74 (6): 439–444. doi:10.1080/17843286.2018.1543827. PMID30477405. S2CID53738534.
Dhondt B, Buelens S, Van Besien J, Beysens M, De Bleser E, Ost P, Lumen N (2019). “Abiraterone and spironolactone in prostate cancer: a combination to avoid”. 《Acta Clinica Belgica》 74 (6): 439–444. doi:10.1080/17843286.2018.1543827. PMID30477405. S2CID53738534.
Scowcroft H (2011년 9월 21일). “Where did abiraterone come from?”. 《Journal of Medicinal Chemistry》 (Cancer Research UK) 38 (13): 2463–2471. 2011년 9월 25일에 원본 문서에서 보존된 문서. 2011년 9월 28일에 확인함.